Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of HLX07 monotherapy in advanced or metastatic cutaneous squamous cell carcinoma
CTR20220564Phase 2Active
- Sponsor
- Henlius
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pimurutamab in cutaneous squamous cell carcinoma (cSCC), sponsored by Henlius. Started Jun 2022; status: active.
02
Drugs
pimurutamab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on CTR20220564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220564.